SummaryDexmedetomidine reduces the dose requirements for opioids and anaesthetic agents. We conducted a single-centre, open-label, noncomparative phase II study of the effect of intravenous dexmedetomidine on the dose requirement of propofol to induce loss of consciousness in 49 ASA I and II patients. The initial dexmedetomidine infusion scheme was reduced twice because of adverse events. Forty patients who received the final infusion scheme were randomly allocated to receive one of five stepped propofol infusions; loss of consciousness was assessed after 21 min. The ED 50 for the final infusion rate of propofol to suppress consciousness was 3.45 mg.kg 21 .h 21 (95% CL 2.7±4.2): ED 95 was 6.68 mg.kg 21 .h 21 (95% CL 5.1±19.1), EC 50 was 1.69 m g.ml 21 (95% CL 0.95±2.5) and EC 95 was 5.7 m g.ml 21 (95% CL 3.2 to . 10). Our final dose of dexmedetomidine of 0.63 m g.kg 21 caused a reduction in the overall concentration and dose of propofol required to produce loss of consciousness, but no significant shift in the dose±response curve compared with other studies. Drugs acting as agonists at a 2 -adrenoceptors may enhance anaesthesia by producing dose-related sedation, anxiolysis, decreased upper airway secretions, peri-operative haemodynamic stability and analgesia [1±3]. There is substantial evidence that the a 2 -agonists also exert an anaestheticsparing effect mediated in part through a decrease in central noradrenergic activity, but mainly through a direct effect on central a 2 -adrenoceptors in the locus coeruleus and other sites [4,5]. The a 2 -agonists also have activity at the imidazoline receptors involved in central blood pressure control [2,6,7].Dexmedetomidine, a specific, selective and potent a 2 -adrenoceptor agonist has been shown to have significant anaesthetic, sedative and analgesic-sparing effects in clinical studies [8±12]. Recently, the dose-dependent effects of dexmedetomidine on isoflurane [11] and sevoflurane [12] requirements have been assessed in humans. However, to date, no studies have explored the shift of a dose±response curve for intravenous agents in conjunction with the a 2 -agonists. We aimed to perform a descriptive dose-finding study to determine the effect of an infusion of dexmedetomidine on the dose and blood concentration of propofol required to suppress consciousness and motor activity during total intravenous anaesthesia with propofol and alfentanil.